Skip to content
COMy 2023 symposium evaluation form
Feedback:
*
Please provide the following information
(Required.)
First name:
Last name:
Email:
Degree:
Country:
Quick feedback
: This helps us to design the most relevant educational programs for you.
Please rate the following: (1=Poor, 10=Excellent)
10
9
8
7
6
5
4
3
2
1
Overall quality of this symposium
10
9
8
7
6
5
4
3
2
1
Design and format
10
9
8
7
6
5
4
3
2
1
The relevance of the topics covered in this symposium
10
9
8
7
6
5
4
3
2
1
*
How well did the learning activity fulfil the following learning objectives?
After this symposium, I am able to:
(Required.)
Extremely well
Very well
Quite well
Not well at all
Describe the therapeutic changes in the treatment landscape of MM and the advantages brought by new immunotherapy agents
Extremely well
Very well
Quite well
Not well at all
Discuss sequencing strategies and factors influencing treatment selection for subsequent treatment lines
Extremely well
Very well
Quite well
Not well at all
Analyze available data on ADCs in relapsed MM and strategies to manage AEs associated with these agents
Extremely well
Very well
Quite well
Not well at all
*
This activity:
(Required.)
Strongly agree
Agree
Not sure
Disagree
Was based on relevant and current/new evidence
Strongly agree
Agree
Not sure
Disagree
Has increased my knowledge of the subject
Strongly agree
Agree
Not sure
Disagree
Has increased my confidence in this subject
Strongly agree
Agree
Not sure
Disagree
Was focused on competencies relevant to my practice
Strongly agree
Agree
Not sure
Disagree
Will help me improve patient care within my clinical practice
Strongly agree
Agree
Not sure
Disagree
Following completion of this symposium, will you make any measurable changes in practice?
Yes
Possibly, but with further training or Information
I will make no specific changes but it has reinforced my current clinical practice
No, I am unable to at this time
If Yes/Possibly, what changes are you likely to make?
I will apply a better understanding of recent updates in the treatment of patients with MM, and integrate novel agents into my clinical practice
I will confidently select an optimal sequencing strategy for individual patients, based on their history and characteristics, and identify factors that can impact treatment outcomes in patients with MM
I will apply improved management strategies for AEs associated with ADCs in patients with MM
I will make a change not listed here
If “I will make a change not listed here” describe any changes you will make.
If “No, I am unable to at this time”, what are the barriers that prevent you from making changes?
Did you feel there was any bias in the educational content?
Yes
No
If Yes, provide what type of bias did you feel was present?
Commercial (you felt there was undue prominence given to a specific product)
Professional (you felt there was inappropriate influence of a related organisation)
Personal (the personal interests of the speaker caused bias)
Other
If Other, please give details.
Would you recommend this symposium to a colleague?
Yes
No
What topics would you like to see in future educational activities?
